Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck.

Oral oncology

Saleh K, Saada E, Auger N, Mayache-Badis L, Casiraghi O, Bidault F, Bahleda R, Even C.
PMID: 30773349
Oral Oncol. 2019 Apr;91:129-131. doi: 10.1016/j.oraloncology.2019.02.008. Epub 2019 Feb 14.

No abstract available.

Cite
Saleh K, Saada E, Auger N, et al. Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck. Oral Oncol. 2019;91:129-131doi: 10.1016/j.oraloncology.2019.02.008.
Saleh, K., Saada, E., Auger, N., Mayache-Badis, L., Casiraghi, O., Bidault, F., Bahleda, R., & Even, C. (2019). Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck. Oral oncology, 91129-131. https://doi.org/10.1016/j.oraloncology.2019.02.008
Saleh, Khalil, et al. "Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck." Oral oncology vol. 91 (2019): 129-131. doi: https://doi.org/10.1016/j.oraloncology.2019.02.008
Saleh K, Saada E, Auger N, Mayache-Badis L, Casiraghi O, Bidault F, Bahleda R, Even C. Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck. Oral Oncol. 2019 Apr;91:129-131. doi: 10.1016/j.oraloncology.2019.02.008. Epub 2019 Feb 14. PMID: 30773349.
Copy Download .nbib Format: NLM
Can we establish a hierarchy among trastuzumab biosimilar candidates?.

British journal of cancer

Pivot X, Petit T.
PMID: 30002436
Br J Cancer. 2018 Aug;119(3):263-265. doi: 10.1038/s41416-018-0171-1. Epub 2018 Jul 13.

The European patent for intravenous trastuzumab lapsed in 2017, and this stimulated research into a number of trastuzumab biosimilars. Quality assessment of their development and clinical results might enable establishment of a clinical hierarchy of these agents. This editorial...

Cite
Pivot X, Petit T. Can we establish a hierarchy among trastuzumab biosimilar candidates?. Br J Cancer. 2018;119(3):263-265doi: 10.1038/s41416-018-0171-1.
Pivot, X., & Petit, T. (2018). Can we establish a hierarchy among trastuzumab biosimilar candidates?. British journal of cancer, 119(3), 263-265. https://doi.org/10.1038/s41416-018-0171-1
Pivot, Xavier, and Petit, Thierry. "Can we establish a hierarchy among trastuzumab biosimilar candidates?." British journal of cancer vol. 119,3 (2018): 263-265. doi: https://doi.org/10.1038/s41416-018-0171-1
Pivot X, Petit T. Can we establish a hierarchy among trastuzumab biosimilar candidates?. Br J Cancer. 2018 Aug;119(3):263-265. doi: 10.1038/s41416-018-0171-1. Epub 2018 Jul 13. PMID: 30002436; PMCID: PMC6068097.
Copy Download .nbib Format: NLM
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties.

Advances in therapy

Yun J, Kim J, Chung J, Hwang SJ, Park SJ.
PMID: 31102205
Adv Ther. 2019 Jul;36(7):1700-1714. doi: 10.1007/s12325-019-00973-y. Epub 2019 May 17.

INTRODUCTION: Stability information for the trastuzumab biosimilar SB3 is limited to 48 h at 2-8 °C for the reconstituted solution and 24 h at up to 30 °C for diluted solutions. Extended physicochemical stability and biological activity were assessed...

Cite
Yun J, Kim J, Chung J, et al. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties. Adv Ther. 2019;36(7):1700-1714doi: 10.1007/s12325-019-00973-y.
Yun, J., Kim, J., Chung, J., Hwang, S. J., & Park, S. J. (2019). Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties. Advances in therapy, 36(7), 1700-1714. https://doi.org/10.1007/s12325-019-00973-y
Yun, Jihoon, et al. "Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties." Advances in therapy vol. 36,7 (2019): 1700-1714. doi: https://doi.org/10.1007/s12325-019-00973-y
Yun J, Kim J, Chung J, Hwang SJ, Park SJ. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties. Adv Ther. 2019 Jul;36(7):1700-1714. doi: 10.1007/s12325-019-00973-y. Epub 2019 May 17. PMID: 31102205; PMCID: PMC6824460.
Copy Download .nbib Format: NLM
Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis.

Medicine

Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, Jahangir A, Shi Y.
PMID: 27858859
Medicine (Baltimore). 2016 Nov;95(44):e5195. doi: 10.1097/MD.0000000000005195.

BACKGROUND: Trastuzumab targets the human epidermal growth factor receptor 2 oncogene and in combination with first-line therapy results in significantly improved survival outcomes and has thus become standard of care in both adjuvant and metastatic settings. While it is...

Cite
Jawa Z, Perez RM, Garlie L, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine (Baltimore). 2016;95(44):e5195doi: 10.1097/MD.0000000000005195.
Jawa, Z., Perez, R. M., Garlie, L., Singh, M., Qamar, R., Khandheria, B. K., Jahangir, A., & Shi, Y. (2016). Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine, 95(44), e5195. https://doi.org/10.1097/MD.0000000000005195
Jawa, Zeeshan, et al. "Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis." Medicine vol. 95,44 (2016): e5195. doi: https://doi.org/10.1097/MD.0000000000005195
Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, Jahangir A, Shi Y. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine (Baltimore). 2016 Nov;95(44):e5195. doi: 10.1097/MD.0000000000005195. PMID: 27858859; PMCID: PMC5591107.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries